Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03240653 : Gaucherite - A Study to Stratify Gaucher Disease
PhaseN/A
AgesMin: 5 Years Max: N/A
Eligibility
Inclusion Criteria:

Each patient must meet all of the following criteria to be enrolled in this study:

1. Confirmed biochemical diagnosis of Type 1 or Type 3 Gaucher disease

2. Written Ethics Committee (EC) approved informed consent obtained from the patient, or
patient's parent or legal guardian and patient assent if appropriate

3. Male or Female patients ? 5 years of age

4. Willing and able to comply with study schedule and procedures

5. Deceased patients for whom the EC determines that patient data can be collected
without a new consent from the patient

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from the study:

1. Unrelated co-morbid condition limiting life expectancy to less than 6 months

2. Confirmed Type 2 Gaucher Disease

3. Patient or if applicable, parent or legal guardian is unable to comprehend, sign and
date the EC approved informed consent form and patient assent as appropriate

4. If determined unsuitable for the study by the investigator
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03240653      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740